C9 and amyotrophic lateral sclerosis: Given that increased NIRs reduce the toxicity of arginine-rich poly-dipeptides and modify aberrant RBP phase transitions, our study highlights the molecular mechanism for potential C9-ALS/FTD therapeutic targets.